Canadian urological association

Federal government websites often end in. The site is secure, canadian urological association. As we exited the pandemic, healthcare within Canada was forced to take stock of the unmet clinical care needs and assign priorities to address those demands.

McMaster Institute of Urology at St. Published: Robotic-assisted laparoscopic pyeloplasty for ureteropelvic junction obstruction A retrospective review of a high-volume Canadian center Michael Ordon, Aren Mnatzakanian, Melody Djuimo, R. Vangala, Mohammed Bassuony, Ahmed S. Zakaria, Walid Shahrour, Hazem Elmansy. High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experience Hanbo Zhang, Nimira S.

Canadian urological association

The Canadian Urological Association CUA does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website. For comments or information, email Corporate. Privacy Policy. Upcoming Events. Canadian Urological Association Journal. Patient Information and Brochures. Subscribe to. GU Clinical Trials image. Twitter Tweets by CanUrolAssoc. Tweets by CanUrolAssoc.

The census was open from May 26 to August 3, Prostate cancer screening pathway.

Full-length guidelines are reserved for broader topics that require more comprehensive exploration. BPRs provide a more focused, concise summary of the best evidence available on common urological topics to help guide management decisions. Both formats have undergone official CUA guideline approval process. Reproduction of any part of the published CUA guidelines, consensus statements, and best practice reports requires the express written consent of the Canadian Urological Association CUA. McMaster Institute of Urology at St.

Federal government websites often end in. The site is secure. Preview improvements coming to the PMC website in October Learn More or Try it out now. It is well-described that neurological disorders can lead to urological complications, including: urinary incontinence, urinary tract infections UTIs , urolithiasis, sepsis, ureteric obstruction, vesicoureteric reflux VUR , and renal failure. Despite the frequency and potential severity of NLUTD, there are few high-quality studies in the literature to guide urological practices. Prior neurogenic guidelines vary in their clinical assessment, investigations used, and surveillance strategies. The etiology of a NLUTD is often classified based on whether the primary lesion is suprapontine, suprasacral, sacral, or infrasacral.

Canadian urological association

Federal government websites often end in. The site is secure. Preview improvements coming to the PMC website in October Learn More or Try it out now. Prostate cancer remains the most commonly diagnosed non-cutaneous malignancy among Canadian men and is the third leading cause of cancer-related death. In , an estimated 21 men were diagnosed with prostate cancer and men died from the disease; 1 however, prostate cancer is a heterogeneous disease with a clinical course ranging from indolent to life-threatening. Identifying and treating men with clinically significant prostate cancer while avoiding the over-diagnosis and over-treatment of indolent disease remains a significant challenge. Several professional associations have developed guidelines on prostate cancer screening and early diagnosis, but there are conflicting recommendations on how best to approach these issues.

Used motorcycles colorado springs

The aim of answering the first four questions is to provide guidance on prostate cancer screening in general. Balancing the known benefits and risks of PSA screening is difficult and is significantly influenced by personal values. Workforce needs and resource access challenges are topics of importance to the Health Policy and the newly created Advocacy Committees; the data collected can be shared with policymakers to bring forward, in concrete terms, the issues facing Canadian urologists and their patients. The measurement of percent free PSA has been studied as a risk-stratifying tool aimed at distinguishing men at risk from prostate cancer vs. Copy Download. Figure 6. In order to best assist our members and their patients as we faced the post-pandemic new world order, CUA leadership felt it important to obtain the most updated information on the current state of urology in Canada. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. The survey was not offered to members practicing outside Canada, non-urologist associate members, honorary members, senior and retired urologists, or those in training. Mayo Clinic Proc. Predicting high-grade cancer at core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.

Laurence H.

Population-based screening has demonstrated benefits in reducing prostate cancer mortality; however, decisions to proceed with screening should be based upon shared decision-making, recognizing that each patient has a different perspective with regards to the potential benefits and harms of prostate cancer screening and treatment. Prostate Cancer Early Detection, Version 2. Best screening practices When prostate cancer screening is performed, the overarching goal should be the early detection of clinically significant prostate cancer in healthy men while minimizing the detection and treatment of low-risk disease. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. Figure 2. Future surveys will also be invaluable in tracking the impact of changes on urological care as a result of changes in healthcare delivery and general population demographic shifts. Although all of these calculators can be used to estimate the risk of harbouring clinically significant prostate cancer prior to prostate biopsy, they again display only moderate predictive accuracy, which varies across different study populations. Reproduction of any part of the published CUA guidelines, consensus statements, and best practice reports requires the express written consent of the Canadian Urological Association CUA. Intermediate-term risk of prostate cancer is directly related to baseline prostate-specific antigen: Implications for reducing the burden of prostate-specific antigen screening. Multicenter evaluation of the Prostate Health Index to detect aggressive prostate cancer in biopsy-naive men. With varying recommendations on PSA screening, no consensus is established among several professional and government organizations Supplementary Table 1.